We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Drug that Mimics Nicotine May Be Used to Treat Cognitive Disorders

By Biotechdaily staff writers
Posted on 14 May 2007
Researchers have isolated a compound that by acting on the brain cell receptors stimulated by nicotine may be a potential drug candidate for treatment of cognitive disorders such as schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder (ADHD).

Nicotine, which mimics the affects of acetylcholine, acts primarily on the autonomic nervous system. More...
In a dose of less than 50 mg, it can cause respiratory failure and general paralysis. Smaller toxic doses can cause heart palpitations, lowered blood pressure, nausea, and dizziness. A person who smokes inhales approximately 3 mg from one cigarette. This amount increases the heart rate, constricts the blood vessels, and acts on the central nervous system, imparting a feeling of alertness and well-being. Anecdotal evidence suggests that many people with the mental illness use tobacco as a sort of self-medication to help them think more clearly.

Investigators at the University of California, Irvine (USA) searched for compounds that would stimulate nicotine receptors without nicotine's side effects (especially if the nicotine is administered by tobacco smoke).

They reported in the April 30, 2007, online edition of the Proceedings of the [U.S.] National Academy of Sciences that they had found a selective acetyl cholinesterase-positive allosteric modulator that corrected sensory-gating deficits and improved working memory in a rat model.

"We would like to see this lead to a drug that would address specifically the cognitive deficits found in schizophrenia,” said senior author Dr. Kelvin W. Gee, professor of pharmacology, at the University of California, Irvine.


Related Links:
University of California, Irvine

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.